Earnings ·
Reports Q3 net loss of $9.8M and $444M cash as NDA submission nears completion
CMPSCOMPASS Pathways plc
Compass Pathways reported a third-quarter 2026 net loss of $9.8 million, or $0.07 per share basic, compared to a $137.7 million loss in the prior-year period. The improvement was primarily driven by a $40.8 million non-cash gain from fair value adjustments on warrant liabilities. For the nine months ended September 30, 2026, the company reported a net loss of $172.4 million, or $1.35 per share. Research and development expenses decreased to $23.5 million for the quarter, while selling, general and administrative expenses rose to $33.0 million due to commercial preparation costs. The company ended the quarter with $444.0 million in cash and cash equivalents, providing runway into 2028. Business highlights include the final New Drug Application (NDA) submission for COMP360 nearing completion, expected within two weeks, with a launch targeted for the first half of 2027 subject to FDA approval. Compass Pathways is a biotechnology company developing psychedelic treatments for mental health conditions.